The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Chemotherapy dose density and effect on prognosis for patients with resectable pancreas cancer: A secondary analysis of SWOG S1505.
 
Sameer H. Patel
No Relationships to Disclose
 
Sarah Colby
No Relationships to Disclose
 
Davendra Sohal
Honoraria - Foundation Medicine
Consulting or Advisory Role - Ability Pharma; AstraZeneca/MedImmune; Bayer; Torus Pharma
Speakers' Bureau - Genentech; Incyte
Research Funding - Ability Pharma (Inst); Amgen (Inst); Apexigen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); FibroGen (Inst); Genentech (Inst); Incyte (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst)
 
Katherine A Guthrie
No Relationships to Disclose
 
Lisa A. Kachnic
Consulting or Advisory Role - New B Innovation
Research Funding - Varian Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
E. Gabriela Chiorean
Consulting or Advisory Role - Astellas Pharma; Axiom Healthcare Strategies; Bayer; Bristol-Myers Squibb/Celgene; Cardiff Oncology; Foundation Medicine; G1 Therapeutics; IgM Biosciences; Ipsen; Merck; Merus; Novartis; Pfizer; Stemline Therapeutics
Research Funding - AADi (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Erasca, Inc; FibroGen (Inst); Gilead/Forty Seven; Lonza (Inst); Merck (Inst); Novartis; Rafael Pharmaceuticals (Inst); Roche (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - G1 Therapeutics
 
Andrew M. Lowy
No Relationships to Disclose
 
Flavio G Rocha
Consulting or Advisory Role - Medtronic
Research Funding - Gunze
Travel, Accommodations, Expenses - Lynx Group
 
Philip Agop Philip
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb/Medarex; Celgene; Daiichi Sankyo/Astra Zeneca; Guardant Health; Guardant Health; incyte; Ipsen; Merck; Rafael Pharmaceuticals; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Bristol-Myers Squibb/Medarex; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals
 
Syed Ahmad
No Relationships to Disclose